David Borg

Sökresultat

• 2023

  An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers

  Mezheyeuski, A., Backman, M., Mattsson, J., Martín-Bernabé, A., Larsson, C., Hrynchyk, I., Hammarström, K., Ström, S., Ekström, J., Mauchanski, S., Khelashvili, S., Lindberg, A., Agnarsdóttir, M., Edqvist, P. H., Huvila, J., Segersten, U., Malmström, P-U., Botling, J., Nodin, B., Hedner, C., & 10 andraBorg, D., Brändstedt, J., Sartor, H., Leandersson, K., Glimelius, B., Portyanko, A., Ponten, F., Jirström, K., Micke, P. & Sjöblom, T., 2023, I: EBioMedicine. 88, s. 1-18 104452.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Tumor Microenvironment 100%
  • Immunotherapy 84%
  • Marker 84%
  • Neoplasms 31%
  • Macrophages 25%
• 2022

  High infiltration of CD68+/CD163- macrophages is an adverse prognostic factor after neoadjuvant chemotherapy in esophageal and gastric adenocarcinoma

  Svensson, M. C., Svensson, M., Nodin, B., Borg, D., Hedner, C., Hjalmarsson, C., Leandersson, K. & Jirström, K., 2022, I: Journal of Innate Immunity. 14, 6 , s. 615-628

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Adenocarcinoma 100%
  • Stomach 91%
  • Macrophages 89%
  • Drug Therapy 75%
  • Neoplasms 41%
• 2021

  Development of a novel weighted ranking method for immunohistochemical quantification of a heterogeneously expressed protein in gastro-esophageal cancers

  Richards, C. E., Sheehan, K. M., Kay, E. W., Hedner, C., Borg, D., Fay, J., O’grady, A., Hill, A. D. K., Jirström, K. & Hopkins, A. M., 2021, I: Cancers. 13, 6, 12 s., 1286.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Junctional Adhesion Molecule A 100%
  • human ERBB2 protein 70%
  • Esophageal Neoplasms 58%
  • Proteins 21%
  • Breast Neoplasms 13%

• T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival

  Svensson, M. C., Lindén, A., Nygaard, J., Borg, D., Hedner, C., Nodin, B., Leandersson, K. & Jirström, K., 2021 maj 20, I: OncoImmunology. 10, 1, 14 s., 1921443.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Adenocarcinoma 100%
  • B-Lymphocytes 98%
  • Stomach 91%
  • T-Lymphocytes 78%
  • Drug Therapy 75%

• The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types

  Micke, P., Strell, C., Mattsson, J., Martín-Bernabé, A., Brunnström, H., Huvila, J., Sund, M., Wärnberg, F., Ponten, F., Glimelius, B., Hrynchyk, I., Mauchanski, S., Khelashvili, S., Garcia-Vicién, G., Molleví, D. G., Edqvist, P. H., O´Reilly, A., Corvigno, S., Dahlstrand, H., Botling, J., & 17 andraSegersten, U., Krzyzanowska, A., Bjartell, A., Elebro, J., Heby, M., Lundgren, S., Hedner, C., Borg, D., Brändstedt, J., Sartor, H., Malmström, P. U., Johansson, M., Nodin, B., Backman, M., Lindskog, C., Jirström, K. & Mezheyeuski, A., 2021, I: EBioMedicine. 65, 103269.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Machine Learning 100%
  • Estrogen 94%
  • Neoplasms 28%
  • Sweden 10%
  • Lions 8%
• 2020

  Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial

  Borg, D., Sundberg, J., Brun, E., Kjellén, E., Petersson, K., Hermansson, M., Johansson, J., Eberhard, J. & Johnsson, A., 2020, I: Acta Oncologica. 59, 2, s. 212-218 7 s.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Deglutition Disorders 100%
  • Adenocarcinoma 77%
  • Radiotherapy 68%
  • Drug Therapy 58%
  • Esophagitis 16%

• Tumor-Associated CD68⁺, CD163⁺, and MARCO⁺ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma

  Jeremiasen, M., Borg, D., Hedner, C., Svensson, M., Nodin, B., Leandersson, K., Johansson, J. & Jirström, K., 2020 okt. 23, I: Frontiers in Oncology. 10, 534761.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Adenocarcinoma 100%
  • Macrophages 89%
  • Biomarkers 83%
  • Neoplasms 41%
  • Survival 39%
• 2019

  Expression of PD-L1 and PD-1 in chemoradiotherapy-Naïve esophageal and gastric adenocarcinoma: Relationship with mismatch repair status and survival

  Svensson, M. C., Borg, D., Zhang, C., Hedner, C., Nodin, B., Uhlén, M., Mardinoglu, A., Leandersson, K. & Jirström, K., 2019 mars 13, I: Frontiers in Oncology. 9, MAR, 136.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Death Domain Receptors 100%
  • DNA Mismatch Repair 96%
  • Chemoradiotherapy 86%
  • Adenocarcinoma 63%
  • Stomach 58%

• Towards improved oncological treatment of esophageal and gastric cancer. Clinical and translational studies.

  Borg, D., 2019, Lund: Lund University, Faculty of Medicine. 73 s.

  Forskningsoutput: Avhandling › Doktorsavhandling (sammanläggning)

  Öppen tillgång

  Fil

  • podocalyxin 100%
  • Esophageal Neoplasms 78%
  • Stomach Neoplasms 66%
  • Adenocarcinoma 59%
  • Clinical Studies 52%
  176 Nedladdningar (Pure)
• 2018

  Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment

  Hedner, C., Borg, D., Nodin, B., Karnevi, E., Jirström, K. & Eberhard, J., 2018 maj 1, I: Journal of Clinical Pathology. 71, 5, s. 451-462 12 s.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • human ERBB2 protein 100%
  • Neoadjuvant Therapy 94%
  • Adenocarcinoma 63%
  • Stomach 58%
  • Survival 45%

• Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

  Borg, D., Larsson, A. H., Hedner, C., Nodin, B., Johnsson, A. & Jirström, K., 2018, I: Journal of Translational Medicine. 16, 1, 290.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • podocalyxin 100%
  • Biological Marker 55%
  • Adenocarcinoma 47%
  • Stomach 43%
  • Biomarkers 39%

• Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma

  Siesing, C., Svensson, M. C., Hedner, C., Nodin, B., Borg, D. & Jirstrom, K., 2018, I: Annals of oncology : official journal of the European Society for Medical Oncology. 29, Suppl. 8, s. viii220

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Chemoradiotherapy 100%
  • Lymphocyte Activation 99%
  • Adenocarcinoma 73%
  • Stomach 67%
  • Gene Expression 56%
• 2017

  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial

  Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., Darby, S., De Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J. R., Middleton, G. W., Cummins, S., & 14 andraRoss, P. J., Wasan, H., McDonald, A., Crosby, T., Ma, Y. T., Patel, K., Sherriff, D., Soomal, R., Borg, D., Sothi, S., Hammel, P., Hackert, T., Jackson, R. & Büchler, M. W., 2017, I: The Lancet. 389, 10073, s. 1011-1024

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Capecitabine 100%
  • gemcitabine 88%
  • Pancreatic Neoplasms 75%
  • Survival 13%
  • Random Allocation 11%

• The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma

  Svensson, M. C., Warfvinge, C. F., Fristedt, R., Hedner, C., Borg, D., Eberhard, J., Micke, P., Nodin, B., Leandersson, K. & Jirström, K., 2017 sep. 22, I: Oncotarget. 8, 42, s. 72108-72126 19 s.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Tumor-Infiltrating Lymphocytes 100%
  • Plasma Cells 78%
  • Natural Killer Cells 73%
  • Adenocarcinoma 61%
  • B-Lymphocytes 60%
• 2016

  Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.

  Hedner, C., Borg, D., Nodin, B., Karnevi, E., Jirström, K. & Eberhard, J., 2016, I: PLoS ONE. 11, 2, e0148101.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • ErbB Receptors 100%
  • Adenocarcinoma 82%
  • Stomach 75%
  • Radio 53%
  • Neoplasms 33%

• Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma

  BORG, DAVID., Hedner, C., Gaber, A., Nodin, B., Fristedt, R., Jirström, K., Eberhard, J. & Johnsson, A., 2016, I: Biomarker research. 4, 10.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Interferons 100%
  • Biological Marker 98%
  • Adenocarcinoma 85%
  • Stomach 78%
  • Biomarkers 70%

• Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma

  Borg, D., Hedner, C., Nodin, B., Larsson, A., Johnsson, A., Eberhard, J. & Jirström, K., 2016 juli 29, I: BMC Clinical Pathology. 16, 1, 13.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • podocalyxin 100%
  • Adenocarcinoma 47%
  • Stomach 43%
  • Biomarkers 39%
  • Proteins 22%

• Pancreatic cancer: Yesterday, today and tomorrow

  Ansari, D., Tingstedt, B., Andersson, B., Holmquist, F., Sturesson, C., Williamsson, C., Sasor, A., Borg, D., Bauden, M. & Andersson, R., 2016 aug. 1, I: Future Oncology. 12, 16, s. 1929-1946 18 s.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Pancreatic Neoplasms 100%
  • Radiology 26%
  • Disease Management 26%
  • Neoplasms 17%
  • Pathology 16%

• Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma

  Fristedt, R., Borg, D., Hedner, C., Berntsson, J., Nodin, B., Eberhard, J., Micke, P. & Jirström, K., 2016, I: Journal of Gastrointestinal Oncology. 7, 6, s. 848-859 12 s.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Plasma Cells 100%
  • Adenocarcinoma 78%
  • B-Lymphocytes 76%
  • Stomach 71%
  • Stomach Neoplasms 64%
• 2015

  Discordant HER2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis.

  Hedner, C., Tran, L., Borg, D., Nodin, B., Jirström, K. & Eberhard, J., 2015, I: Histopathology.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • human ERBB2 protein 100%
  • Adenocarcinoma 63%
  • Trastuzumab 32%
  • Stomach Neoplasms 23%
  • Neoplasms 8%
• 2009

  Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor

  Jönsson, M., Isinger Ekstrand, A., Edekling, T., Eberhard, J., Grabau, D., Borg, D. & Nilbert, M., 2009 okt. 15, I: BMC Clinical Pathology. 9, Oct 15, s. 8 8.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Fil

  • Mutation Rate 100%
  • Rectal Neoplasms 96%
  • Mutation 52%
  • Colorectal Neoplasms 46%
  • Neoplasms 30%
  233 Nedladdningar (Pure)